CLASS ACTION UPDATE for TVTY, ANAB and ZM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / April 8, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Tivity Health, Inc. (NASDAQ:TVTY)
TVTY Lawsuit on behalf of: investors who purchased March 8, 2019 – February 19, 2020
Lead Plaintiff Deadline: April 27, 2020
Join the action: https://www.zlk.com/pslra-1/tivity-health-inc-loss-form?wire=3&prid=5958

The lawsuit alleges: Tivity Health, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) following the Nutrisystem Acquisition, Tivity's Nutrition segment faced significant operational challenges; (ii) the foregoing would foreseeably have a significant impact on Tivity's revenues; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more about the Tivity Health, Inc. class action, contact jlevi@levikorsinsky.com.

AnaptysBio, Inc. (NASDAQ:ANAB)
ANAB Lawsuit on behalf of: investors who purchased October 10, 2017 – November 7, 2019
Lead Plaintiff Deadline: May 26, 2020
Join the action: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?wire=3&prid=5958

The lawsuit alleges that, during the class period, AnaptysBio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the AnaptysBio, Inc. class action, contact jlevi@levikorsinsky.com.

Zoom Video Communications, Inc. (NASDAQ:ZM)
ZM Lawsuit on behalf of: investors who purchased April 18, 2019 – April 6, 2020
Lead Plaintiff Deadline: June 8, 2020
Join the action: https://www.zlk.com/pslra-1/zoom-video-communications-inc-loss-form?wire=3&prid=5958

The lawsuit alleges: Zoom Video Communications, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) Zoom had inadequate data privacy and security measures; (ii) contrary to Zoom's assertions, the Company's video communications service was not end-to-end encrypted; (iii) as a result of all the foregoing, users of Zoom's communications services were at an increased risk of having their personal information accessed by unauthorized parties, including Facebook; (iv) usage of the Company's video communications services was foreseeably likely to decline when the foregoing facts came to light; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more about the Zoom Video Communications, Inc. class action, contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 584418